You just read:

REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemia

News provided by

REGENXBIO Inc.

Aug 08, 2018, 07:30 ET